<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856295</url>
  </required_header>
  <id_info>
    <org_study_id>EMC59-12</org_study_id>
    <nct_id>NCT02856295</nct_id>
  </id_info>
  <brief_title>anti10a Levels in Women Treated With LMWH in the Postpartum Period</brief_title>
  <official_title>anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare between anti-10a levels in postpartum women receiving
      different prophylactic doses of LMWH: one group with LMWH doses adjusted by the women's
      weight and the second group receiving 1mg/kg to a maximum dose of 120 mg
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      pregnancy and postpartum period are associated with increased risk of thromboembolism. this
      risk is further increased in women with thrombophilia.

      This risk is higher in the postpartum period compared with pregnancy period, especially the
      risk for pulmonary embolism (PE). The American College Of Obstetrics and Gynecologists, The
      American college of chest physicians and The Royal College of obstetricians and gynecologists
      recommend using low molecular weight heparin during the postpartum period in women with
      thrombophilia and women with risk factor for developing thromboembolism. there is no specific
      guidelines regarding the best protocol based on the level of anti-10 a.

      This study will compare between two protocols based on anti-10a levels.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clexane dosing method in order to achieve anti 10a level &gt;0.2</measure>
    <time_frame>4 hour after the women receive the drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of anti 10a level of &gt;0.6</measure>
    <time_frame>4 hour after the women receive the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of vein thromboembolism</measure>
    <time_frame>during the six weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of bleeding events</measure>
    <time_frame>during the six weeks after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>clexane according to weight group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clexane dose adjusted for woman's weight according to: weight &lt; 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, &gt;170kg-100mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clexane mg per kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clexane dose of 1mg/kg up to 120 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clexane (LMWH)</intervention_name>
    <description>to compare tow doses of clexane for preventing VTE in postpartum women</description>
    <arm_group_label>clexane according to weight group</arm_group_label>
    <arm_group_label>clexane mg per kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postpartum women supposed to receive LMWH according to obstetric indications

        Exclusion Criteria:

          -  known allergy to clexane

          -  active bleeding postpartum

          -  thrombocytopenia &lt; 75000

          -  recent cerebrovascular accident / transient ischemic attack (&lt;4 weeks)

          -  glomerular filtration rate) &lt; 30 ml/min)

          -  active liver disease

          -  malignant hypertension (systolic &gt; 200 mmHg, diastolic&gt; 120 mmHg)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zohar Nachum, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Emek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zohar Nachum, M.D</last_name>
    <phone>972547696562</phone>
    <email>nachum_zo@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abeer Suleiman, M.D</last_name>
    <phone>972503441700</phone>
    <email>abeersulim@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003 Jun;16(2):153-68. Review.</citation>
    <PMID>12763484</PMID>
  </results_reference>
  <results_reference>
    <citation>Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. Review.</citation>
    <PMID>12709915</PMID>
  </results_reference>
  <results_reference>
    <citation>Lockwood C, Wendel G; Committee on Practice Bulletinsâ€” Obstetrics. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol. 2011 Sep;118(3):730-40. doi: 10.1097/AOG.0b013e3182310c6f.</citation>
    <PMID>21860314</PMID>
  </results_reference>
  <results_reference>
    <citation>Scifres CM, Macones GA. The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction? Am J Obstet Gynecol. 2008 Oct;199(4):344.e1-7. doi: 10.1016/j.ajog.2008.04.051. Epub 2008 Jun 24.</citation>
    <PMID>18572147</PMID>
  </results_reference>
  <results_reference>
    <citation>Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999 Nov;94(5 Pt 1):730-4.</citation>
    <PMID>10546719</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang J, Elam-Evans LD, Berg CJ, Herndon J, Flowers L, Seed KA, Syverson CJ. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003 Feb 21;52(2):1-8.</citation>
    <PMID>12825542</PMID>
  </results_reference>
  <results_reference>
    <citation>Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005 Nov 15;143(10):697-706.</citation>
    <PMID>16287790</PMID>
  </results_reference>
  <results_reference>
    <citation>Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008 Apr;6(4):632-7. doi: 10.1111/j.1538-7836.2008.02921.x. Epub 2008 Jan 31.</citation>
    <PMID>18248600</PMID>
  </results_reference>
  <results_reference>
    <citation>McColl MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol. 1999 Aug;106(8):756-66. Review.</citation>
    <PMID>10453824</PMID>
  </results_reference>
  <results_reference>
    <citation>Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-e736S. doi: 10.1378/chest.11-2300.</citation>
    <PMID>22315276</PMID>
  </results_reference>
  <results_reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. Obstet Gynecol. 2002 Oct;100(4):845-6.</citation>
    <PMID>12387283</PMID>
  </results_reference>
  <results_reference>
    <citation>Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014 Feb 11;(2):CD001689. doi: 10.1002/14651858.CD001689.pub3. Review.</citation>
    <PMID>24519568</PMID>
  </results_reference>
  <results_reference>
    <citation>Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):627S-644S. Review.</citation>
    <PMID>15383488</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy. 2011 Jul;31(7):678-85. doi: 10.1592/phco.31.7.678.</citation>
    <PMID>21923455</PMID>
  </results_reference>
  <results_reference>
    <citation>Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol. 2008 Oct;112(4):884-9. doi: 10.1097/AOG.0b013e31818638dc. Erratum in: Obstet Gynecol. 2009 Mar;113(3):742.</citation>
    <PMID>18827132</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Zohar Nachum</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>postpartum venous thromboembolism</keyword>
  <keyword>prophylactic dose of low molecular weight heparin</keyword>
  <keyword>anti 10a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

